NeuroPace (NPCE) to Release Quarterly Earnings on Tuesday

NeuroPace (NASDAQ:NPCE) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $24.7910 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

NeuroPace Stock Performance

NPCE stock opened at $14.56 on Tuesday. NeuroPace has a twelve month low of $7.56 and a twelve month high of $18.98. The company has a quick ratio of 3.94, a current ratio of 4.86 and a debt-to-equity ratio of 3.17. The company has a market cap of $484.99 million, a P/E ratio of -19.16 and a beta of 1.85. The business’s fifty day moving average is $15.88 and its 200-day moving average is $13.03.

Institutional Investors Weigh In On NeuroPace

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of NeuroPace by 4.9% in the third quarter. Vanguard Group Inc. now owns 1,435,850 shares of the company’s stock valued at $14,804,000 after acquiring an additional 66,574 shares during the last quarter. Armistice Capital LLC boosted its holdings in shares of NeuroPace by 12.6% in the 3rd quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock valued at $13,382,000 after buying an additional 145,665 shares during the last quarter. Kotler Kevin bought a new position in shares of NeuroPace in the fourth quarter valued at $9,750,000. Geode Capital Management LLC raised its position in NeuroPace by 6.5% during the fourth quarter. Geode Capital Management LLC now owns 596,248 shares of the company’s stock worth $9,208,000 after acquiring an additional 36,516 shares in the last quarter. Finally, State Street Corp grew its position in shares of NeuroPace by 9.8% in the 4th quarter. State Street Corp now owns 447,864 shares of the company’s stock valued at $6,915,000 after acquiring an additional 40,025 shares during the period. 78.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NPCE. Leerink Partners restated an “outperform” rating and set a $19.00 target price on shares of NeuroPace in a report on Wednesday, November 5th. JPMorgan Chase & Co. lifted their price objective on shares of NeuroPace from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price target on shares of NeuroPace in a research report on Wednesday, November 5th. Wells Fargo & Company lifted their target price on NeuroPace from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroPace in a report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

About NeuroPace

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.